As for the future, Mojsov is optimistic. She foresees a new generation of similar drugs that will further minimize side effects and target an even broader range of diseases.
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approvalAdvancing path to IND submission for first-in-human trialsSARASOTA, ...
Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so what was that journey like for the scientists involved? Joel Habener of ...
As for the future, Mojsov is optimistic. She foresees a new generation of similar drugs that will further minimize side effects and target an even broader range of diseases.
As for the future, Mojsov is optimistic. She foresees a new generation of similar drugs that will further minimize side effects and target an even broader range of diseases.
Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic ... Habener believed he could uncover new ways to manage diabetes.
New era of treatments - Starting in the 1990s, Knudsen, the head of GLP-1 therapeutics at Novo Nordisk, and her team built on these breakthroughs to develop treatments for diabetes (Ozempic) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback